Tag:

Europe

Latest Headlines

Latest Headlines

Stryker to repatriate $2B, ready for acquisitions in 2H15

Stryker took an earnings hit during the third quarter, in part to repatriate $2 billion in cash for acquisitions and to establish an EU regional headquarters in Amsterdam, where it has moved some intellectual property. The IP transfer is expected to reduce its effective tax rate from an expected 22% in 2014 to 20% next year.

Ireland to end 'Double Irish,' Innovations talks investment plan, German biotechs bag €15M

In this week's EuroBiotech Report, AbbVie showed that efforts to clamp down on inversions are having an effect, while Ireland committed to closing the door on the "Double Irish" tax scheme. And more.

New U.K. biotech bags £15.5M, Forbion plans €200M fund, Serono strikes oncology deal

Welcome to the latest edition of our weekly  EuroBiotech Report.

EU halts distribution of GI Dynamics obesity device

The European Union suspended shipments of EndoBarrier, an obesity device from GI Dynamics, for reasons undisclosed by the company. GI Dynamics said the situation is temporary and does not apply to product already in the hands of hospitals and distributors.

Optos, NHS and academia in $16M partnership for eye disease diagnostic

Medical retinal imaging player Optos, the U.K. National Health Service and academics will participate in a £10 million ($16 million) collaboration to enable earlier detection of eye diseases that threaten vision.

EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal

The European Union's antitrust unit is worried that Zimmer's $13.4 billion bid for crosstown rival Biomet will limit competition and wants to look into the deal further.

Karolinska Development's CEO leaves, Erytech hits PhIII endpoints, VBL belatedly nails IPO

Welcome to the latest edition of our weekly EuroBiotech Report.

Consort Medical strikes $374M deal to buy Aesica

Consort Medical has placed a big bet on the convergence of drug and device production services, striking a £230 million ($374 million) deal to buy European contract manufacturer Aesica Pharmaceuticals. 

Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

Gilead nears EU approval for the next big thing in hep C

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections.